SUMMARY Ten-year results are reported from a randomised controlled trial of anti-smoking advice in 1445 male smokers, aged 40-59, at high risk of cardiorespiratory disease. After one year, reported cigarette consumption in the intervention group (714 men) was one-quarter that of the "normal care" group (731 men); over 10 years the nett reported reduction averaged 53%. The intervention group experienced less nasal obstruction, cough, dyspnoea, and loss of ventilatory function. Over 10 years their mortality from coronary heart disease was 18% lower than controls (49 and 62 deaths), and that for lung cancer was 23% lower (18 and 24 deaths). Deaths from non-lung cancers were higher in the intervention group (28 v 12 deaths). This unexpected difference was due about equally to an excess in intervention and a deficiency in normal care men, it showed no site specificity, and it was unrelated to change in smoking habit. These findings suggest that it is more likely to have been due to chance than to intervention. The total number of deaths were 123 in the intervention group and 128 in normal care (95% confidence limits of difference -22% to + 23%). The policy of encouraging smokers to give up the habit should not be changed. The results, which were first sent to general practitioners, were used to select 1445 cigarette smokers with the highest risk of coronary heart disease or chronic bronchitis, or both, based on a multivariate combination of risk factor levels. These men were divided randomly into two groups. Those in the "intervention" group (714 men) were recalled for individual advice on the relation of smoking to their health, and they were challenged to consider their situation. Those (the large majority) who declared a wish to stop smoking were given support and encouragement, continuing on average for four further visits over the ensuing 12 months. No other health advice was given, except on calorie restriction for those who gained weight.
The health of ex-smokers and continuing smokers has been compared in many observational studies; but the results are not easy to interpret, since ex-smokers are not a random selection of former smokers. Their history of smoking tends to differ, not only in the amount smoked (which can be allowed for) but also in inhalation and choice of brand; and subtle interactions between these factors make it difficult to allow for their effects.' They may differ moreover in other sorts of health-related behaviour, as well as in social class and environment and in preceding levels of risk factors.2 Furthermore, the decision to stop smoking may have been prompted by ill health, and this would leave ex-smokers with an impaired prognosis. For all these reasons the lower mortality of ex-smokers observed in most studies does not simply reflect the effect of stopping smoking. Only a randomised controlled trial of stopping smoking can offer an unbiased comparison.
In 1968 we set up such a trial as part of the Whitehall Study.3 Preliminary results have been reported.' At that time, after an average of 7 * 9 years' follow-up, deaths were too few to warrant 'Present The results, which were first sent to general practitioners, were used to select 1445 cigarette smokers with the highest risk of coronary heart disease or chronic bronchitis, or both, based on a multivariate combination of risk factor levels. These men were divided randomly into two groups. Those in the "intervention" group (714 men) were recalled for individual advice on the relation of smoking to their health, and they were challenged to consider their situation. Those (the large majority) who declared a wish to stop smoking were given support and encouragement, continuing on average for four further visits over the ensuing 12 (table 1) . After one year in the trial, and again after three years, men in both the intervention and normal care groups received a self-administered questionnaire on current smoking habits, symptoms and recent illnesses, together with an appointment for a physical examination. A further postal inquiry about smoking habits was undertaken after men had been in the trial for about nine years. The records of all participants were "flagged" at the National Health Service Central Registry, which provided coded copies of all death certificates and (for the period 1971-9) of cancer registrations. In deaths ascribed to cancer we wrote to the hospital doctors, seeking details of histological verification. The present report analyses 10 years' experience of mortality and notified incidence of cancer.
Results

CHANGES IN SMOKING HABIT
The questionnaire response rates among survivors were 84% at one year, 70% at three years, and 83% at nine. Losses were mainly in retired men. In the intervention group the proportion of responders who said that they were not smoking any cigarettes was 63% at one year, 57% at three years, and 55% at nine. Mean daily cigarette consumption reported by normal care and intervention groups at initial survey, and entry to trial, one-year and three-year re-examinations, and final postal inquiry.
Geoffrey Rose, P J S Hamilton, L Colwell, and M J Shipley Causes of death were also grouped according to whether or not they are smoking-related.* There were 92 such deaths in the normal care group and 81 in the intervention, a proportionate change of -9% (95% cl -3 1% to + 20%).
Discussion
The causal role of cigarette smoking in coronary heart disease, lung cancer, and chronic bronchitis and emphysema is widely accepted. For the respiratory diseases this explanation probably accounts for nearly all of their observed association with smoking; but for coronary heart disease this is less certain, especially in older people. Thus life-long avoidance ' That is, coronary heart disease (ICD 410-4), chronic bronchitis (491), and cancers of the respiratory tract (140, , oesophagus (150), urinary tract (188-9) and pancreas (157). group.bmj.com on April 13, 2017 -Published by http://jech.bmj.com/ Downloaded from Geoffrey Rose, P J S Hamilton, L Colwell, and M J Shipley of cigarettes can be expected to reduce the risk of each of these conditions to an extent ranging from near-complete avoidance of lung cancer down to a smaller and less certainly definable reduction in coronary heart disease.
The cigarette-induced damage that may culminate in disability and death is the outcome of many years of exposure, accompanied by progressive pathological changes that are not necessarily reversible. Studies that have compared continuing and ex-smokers have nevertheless nearly all observed a large apparent advantage to the latter,"; but such comparisons could be biased by the differences, both known and unknown, between those in the population who choose to continue smoking and those who choose to stop. This objection does not apply to the observed fall in mortality from smoking-related causes among British doctors as a whole, over a period in which their smoking greatly declined7, but it is possible that other factors may have contributed. Only a randomised trial offers a direct test of the reversibility of the risks from smoking. Such a trial presents formidable difficulties, and unfortunately the present report seems likely to stand as the only such single-factor randomised controlled study. Less direct evidence may come from some of the current multifactor intervention trials. Incidence results from the UK heart disease prevention project' do not suggest any excess of cancer risk among the 9734 men in the intervention group; and in the Oslo trial10 there were five deaths from cancer in the intervention group compared with eight in controls.
The trial was designed to test whether the total reduction in cardiorespiratory disease among middle-aged men was as large as that indicated by the observational studies of ex-smokers. Its size was planned in the expectation that incidence as well as mortality data would be available; when this proved unattainable, the loss of power was partly offset by extending the mortality follow-up to 10 years. A larger trial would have been better; but the screening of over 16 000 men, and repeated personal interviews with over 700 of them, stretched our resources to the limit.
The reduction in smoking among intervention subjects was a little better than expected, with almost two-thirds of those attending the one-year follow-up examination claiming to have given up cigarettes altogether, and most of the others claiming to be smoking much less than before. Objective tests of smoking behaviour were not available to us at that time. No doubt there was exaggeration of claims to have cut down, but we thought that those reporting complete cessation were generally truthful. The reports were based on questionnaires completed at home, with little external pressure; and they were largely consistent over the ensuing years, the progressively narrowing gap between the two groups being due mainly to a gradual reduction in smoking by normal care men. Thus although the size of the gap may have been overestimated, there is no doubt that throughout the earlier years of the trial it was large.
If the trial had been started a few years later we should have done more to discourage pipe and cigar smoking by intervention subjects, since it now seems that in former cigarette smokers this may often be associated with continued inhalation. The continuing pipe and cigar smokers are not a randomly chosen group, but in general their risks for both cardiovascular and respiratory causes of death did not seem to be much different from those who gave up smoking entirely.
Over the trial as a whole the intervention group's level of smoking exposure was estimated as about half that of the normal care group, implying that the best estimates of the effects of complete cessation might be about double those observed in the trial. For coronary heart disease mortality the latter was -18%, which is in fact the same as was observed in the first 10 years follow-up of the British doctors study."1 The pattern observed in the trial suggested a gradually accumulating benefit, and in this respect it supports the large longitudinal surveys rather than the apparently immediate benefit reported among survivors of myocardial infarction,1214 or, based on small numbers, by the Framingham study ."5 Lung cancer mortality was 23% lower in the intervention group, but this estimate of benefit fell to 8% if other registered cases were included. (Most of the latter are dead from various causes other than lung cancer, and therefore appear in the total for all deaths.) Again, allowing for non-adherence, either of these estimates is within sampling limits of the prediction based on observational studies.
As set out in our previous report,' respiratory morbidity was considerably improved by stopping smoking. The commonest benefit, much appreciated by the men but curiously overlooked in previous reports, was a reduction in nasal obstruction. There were also the expected improvements in bronchitic symptoms, and a slowing in the rate of loss of ventilatory function. Deaths from bronchitis and emphysema were too few to asssess (four in normal care and four in intervention men).
When the trial was planned the only possible adverse effect envisaged was psychological (which proved to be only minor). It 
